HGF targeting antibodies, including rilotumumab (AMG-102), ficlatuzumab, TAK-701, and YYB-101, bind to HGF and prevent c-Met attachment, leading to the induction of synergistic anti-tumor responses combined with other TKIs and EGFR inhibitors [162, 172, 178, 179]. The gene discussed is MET; the disease is neoplasm.